
    
      The aim of this study is to assess the efficacy -as determined by the proportion of patients
      with normalization of SpO2 â‰¥96% on room air- of continued standard care together with
      tocilizumab plus pembrolizumab (MK- 3475) in patients with COVID-19 pneumonia
    
  